| 张小岑,毛国顺,朱 影,李亚彬,叶玉兰.乙酰半胱氨酸辅助治疗小儿支原体肺炎的疗效及对CD分子含量的影响[J].,2020,(10):1961-1965 |
| 乙酰半胱氨酸辅助治疗小儿支原体肺炎的疗效及对CD分子含量的影响 |
| Clinical efficacy of Acetylcysteine Adjuvant Therapy Mycoplasma Pneumonia in the Treatment of Children and Its Effect on the Content of CD Molecular |
| 投稿时间：2020-01-06 修订日期：2020-01-30 |
| DOI：10.13241/j.cnki.pmb.2020.10.036 |
| 中文关键词: 小儿支原体肺炎 乙酰半胱氨酸 阿奇霉素 红霉素 CD分子含量 |
| 英文关键词: Mycoplasma pneumonia in children Acetylcysteine Azithromycin Erythromycin CD molecular content |
| 基金项目:安徽省自然科学基金项目(1608085QH188) |
|
| 摘要点击次数: 732 |
| 全文下载次数: 440 |
| 中文摘要: |
| 摘要 目的：探讨乙酰半胱氨酸辅助治疗小儿支原体肺炎的疗效及对CD分子含量的影响。方法：选择2019年1月至2019年12月我院收治的90例支原体肺炎患儿，通过随机数表法分为观察组和对照组，每组45例。对照组给予常规处理，观察组在对照组基础上，联合吸入乙酰半胱氨酸溶液治疗，两组均连续治疗5 d。比较两组临床疗效、症状消失时间、住院时间、治疗前后、白细胞计数(WBC)、C反应蛋白(CRP)、CD3+、CD4+、CD4+/CD8+的变化及不良反应的发生情况。结果：治疗后，观察组临床疗效总有效率为93.33%，明显高于对照组(77.78%，P＜0.05)；观察组咳嗽及肺啰音消失时间、住院时间明显短于对照组[(5.24±1.07)d vs (6.59±1.16)d，(5.53±0.76)d vs (6.75±1.04)d，(7.01±1.40)d vs (8.11±1.36)d](P＜0.05)；观察组白细胞计数(WBC)、C反应蛋白(CRP)明显低于对照组[(5.06±0.72)×109/L vs(7.34±1.30)×109/L，(1.86±0.20)mg/L vs (4.63±0.61)mg/L]，CD3+、CD4+、CD4+/CD8+明显高于对照组[(64.81±5.63)% vs(58.03±4.27)%，(36.86±3.09)% vs(29.17±2.64)%，(1.32±0.18)% vs(1.20±0.12)%](P＜0.05)。两组治疗期间均未见明显不良反应。结论：乙酰半胱氨酸辅助治疗小儿支原体肺炎效果明显，其有助于促进疾病恢复，且安全性好，其内在机制可能和调节CD分子含量、修复免疫紊乱等相关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical efficacy of acetylcysteine adjuvant therapy mycoplasma pneumonia in the treatment of children and its effect on the content of CD molecular. Methods: 90 children with mycoplasma pneumonia who received therapy from January 2019 to December 2019 in our hospital were selected, according to the random number table, they were divided into the observation group and the control group, each group had 45 cases. The control group was given routine treatment, on the basis of the control group, the observation group was combined with acetylcysteine solution inhalation, they were treated for 5 days. The clinical efficacy, symptoms disappear time, hospital stay, the changes of the white blood cell count (WBC), C reactive protein (CRP), CD3+, CD4+ and CD4+/CD8+ before and after treatment, and the occurrence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate in the observation group was 93.33%, which was significantly higher than that of the control group 77.78%(P＜0.05); the disappearance time of cough, pulmonary rales and hospital stay in the observation group were significantly shorter than that of the control group[(5.24±1.07)d vs (6.59±1.16)d, (5.53±0.76)d vs (6.75±1.04)d, (7.01±1.40)d vs (8.11±1.36)d](P＜0.05); the leukocyte count (WBC), C-reactive protein (CRP) in the observation group were significantly lower than that of the control group[(5.06±0.72)×109/L vs (7.34±1.30)×109/L, (1.86±0.20)mg/L vs (4.63±0.61)mg/L], the CD3+, CD4+ and CD4+/CD8+ were significantly higher than that of the control group[(64.81±5.63)% vs (58.03±4.27)% ,(36.86±3.09)% vs (29.17±2.64)%, (1.32±0.18)% vs (1.20±0.12)%](P＜0.05). There were no obvious adverse reactions in the two groups during the treatment. Conclusion: Acetylcysteine adjuvant therapy is effective for mycoplasma pneumonia in children, it can promote disease recovery with high safety, the internal mechanism may be related to the regulation of CD molecular content, repair of the immune function and so on. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
